Viewing Study NCT06235918


Ignite Creation Date: 2025-12-25 @ 4:31 AM
Ignite Modification Date: 2025-12-26 @ 3:33 AM
Study NCT ID: NCT06235918
Status: RECRUITING
Last Update Posted: 2024-02-01
First Post: 2024-01-22
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
Sponsor: Xiang Lu
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module